

Serial No.: Unknown  
Docket No. B45082D1

*Sub D1*  
*Sub 2*  
16. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 15, wherein the second Varicella Zoster protein is selected from the group, gpI, gpII, gpIII, gpIV, gpV or IE62 or immunological functional derivative thereof.

17. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 13, additionally comprising an adjuvant.

*Sub D1*  
18. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 17, wherein the adjuvant preferentially induces a TH1 response.

*B1*  
19. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 18, wherein the antigen is presented as an oil in water emulsion together with QS21 and 3D-MPL.

*Sub 3*  
20. A method of producing a pharmaceutical composition comprising a Varicella Zoster virus IE63 protein, nucleic acid or immunologically functional derivative thereof, comprising mixing said protein, nucleic acid or derivative with a pharmaceutically acceptable excipient.

*Sub 4*  
21. A method as claimed in claim 20, wherein the excipient comprises an adjuvant.